JPMorgan Chase & Co. Acquires 40,721 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

JPMorgan Chase & Co. increased its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 94.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,826 shares of the company's stock after acquiring an additional 40,721 shares during the period. JPMorgan Chase & Co.'s holdings in Takeda Pharmaceutical were worth $1,110,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of TAK. World Investment Advisors LLC bought a new stake in shares of Takeda Pharmaceutical in the 3rd quarter valued at approximately $258,000. Wilmington Savings Fund Society FSB bought a new stake in Takeda Pharmaceutical in the third quarter worth approximately $40,000. Franklin Resources Inc. acquired a new position in shares of Takeda Pharmaceutical during the 3rd quarter worth $244,000. B. Riley Wealth Advisors Inc. bought a new position in shares of Takeda Pharmaceutical during the 3rd quarter valued at $163,000. Finally, Versant Capital Management Inc acquired a new stake in shares of Takeda Pharmaceutical in the 4th quarter valued at $26,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

Shares of TAK traded up $0.31 during mid-day trading on Friday, hitting $15.34. The company's stock had a trading volume of 267,656 shares, compared to its average volume of 1,864,966. Takeda Pharmaceutical Company Limited has a one year low of $12.58 and a one year high of $15.38. The stock's 50-day moving average is $14.82 and its two-hundred day moving average is $13.96. The firm has a market capitalization of $48.79 billion, a PE ratio of 38.34, a price-to-earnings-growth ratio of 0.24 and a beta of 0.39. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, sell-side analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.